Want to see HK:2633 full AI Analyst Report?
Top Page
Jacobson Pharma Corporation Limited
(2633)
Select Model
Select Model
Rating:70Outperform
Price Target:
HK$1.00
â–¼(-22.48% Downside)
Action:Reiterated
Date:10/21/26
The score is supported mainly by solid financial performance (strong profitability and improved leverage) and very attractive valuation (low P/E and high dividend yield). Offsetting factors are weaker cash-flow momentum (notable FCF decline) and a soft technical setup with the price below key longer-term moving averages.
Positive Factors
Strong Profitability
Strong gross and net margins indicate that Jacobson Pharma is converting sales into meaningful earnings, supporting internal funding for product development, manufacturing, and distribution. Improved profitability versus earlier years also suggests stronger earnings power and a more resilient operating model over the next several quarters.
Negative Factors
Revenue Growth Volatility
Volatile revenue performance makes future earnings less predictable and indicates that the company has not yet established a consistently expanding growth trajectory. Modest latest-period growth may limit operating leverage, reduce visibility for reinvestment, and make margin progress harder to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
Strong gross and net margins indicate that Jacobson Pharma is converting sales into meaningful earnings, supporting internal funding for product development, manufacturing, and distribution. Improved profitability versus earlier years also suggests stronger earnings power and a more resilient operating model over the next several quarters.
Read all positive factors
Jacobson Pharma Corporation Limited (2633) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.80B
Dividend Yield9.57%
Average Volume (3M)306.70K
Price to Earnings (P/E)6.3
Beta (1Y)0.11
Revenue Growth-0.47%
EPS Growth-0.40%
CountryHK
Employees1,768
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.15
Shares Outstanding2,000,221,000
10 Day Avg. Volume290,231
30 Day Avg. Volume306,697
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.57
P/FCF Ratio12.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.16
Revenue Forecast (FY)HK$1.63B
Jacobson Pharma Corporation Limited Business Overview & Revenue Model
Company Description
Jacobson Pharma Corporation Limited, a subsidiary of Kingshill Development Limited, specializes in the production, promotion, and distribution of generic medications and branded healthcare products. Its market reach extends across Hong Kong, mainl...
How the Company Makes Money
Jacobson Pharma primarily makes money by selling pharmaceutical and healthcare products through a mix of distribution and self-developed/manufactured product sales. Key revenue streams typically include: (1) sales of proprietary or in-licensed pha...
Jacobson Pharma Corporation Limited Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
74
Positive
Cash Flow
58
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.57B | 1.58B | 1.47B | 1.79B | 1.60B |
| Gross Profit | 677.90M | 692.94M | 620.48M | 747.17M | 620.52M |
| EBITDA | 506.97M | 558.87M | 475.11M | 462.04M | 415.49M |
| Net Income | 301.62M | 300.83M | 266.97M | 251.04M | 177.67M |
Balance Sheet | |||||
| Total Assets | 3.56B | 3.65B | 3.49B | 5.38B | 4.76B |
| Cash, Cash Equivalents and Short-Term Investments | 369.86M | 509.05M | 411.94M | 1.04B | 478.65M |
| Total Debt | 910.90M | 773.21M | 749.38M | 1.60B | 1.41B |
| Total Liabilities | 1.22B | 1.17B | 1.09B | 2.12B | 1.80B |
| Stockholders Equity | 2.32B | 2.45B | 2.37B | 2.74B | 2.49B |
Cash Flow | |||||
| Free Cash Flow | 200.52M | 278.39M | 354.85M | 585.23M | 345.89M |
| Operating Cash Flow | 336.70M | 526.78M | 484.36M | 648.24M | 409.76M |
| Investing Cash Flow | -232.70M | -297.76M | 43.34M | -44.09M | -52.75M |
| Financing Cash Flow | -242.18M | -131.30M | -1.05B | -45.64M | -357.89M |
Jacobson Pharma Corporation Limited Technical Analysis
Neutral
1.29
Price Trends
0.97
Negative
0.99
Negative
1.08
Negative
Market Momentum
>-0.01
Positive
50.50
Neutral
39.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2633, the sentiment is Neutral. The current price of 1.29 is above the 20-day moving average (MA) of 0.96, above the 50-day MA of 0.97, and above the 200-day MA of 1.08, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.50 is Neutral, neither overbought nor oversold. The STOCH value of 39.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2633.
Jacobson Pharma Corporation Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$774.43M | 7.77 | 13.59% | 7.44% | 10.63% | 39.44% | |
70 Outperform | HK$1.80B | 6.26 | 13.26% | 9.57% | -0.47% | -0.40% | |
59 Neutral | HK$1.41B | 5.21 | 6.78% | 6.74% | 6.55% | 36.62% | |
53 Neutral | HK$5.77B | -4.70 | -4.98% | 0.31% | -15.80% | -298.94% | |
53 Neutral | HK$378.89M | 94.44 | 0.34% | 84.69% | -8.30% | -44.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$124.11M | -4.08 | -21.66% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:2633
Jacobson Pharma Corporation Limited
0.95
-0.40
-29.48%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.15
-1.17
-50.43%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.34
-0.12
-26.09%
HK:1498
PuraPharm Corp. Ltd.
0.23
-0.19
-44.76%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
0.94
-0.19
-17.26%
HK:0239
Pak Fah Yeow International Limited
2.49
0.26
11.54%
Jacobson Pharma Corporation Limited Corporate Events
Jacobson Pharma Wins Shareholder Backing for Dividend, Board Mandates at AGM
Aug 11, 2026
Jacobson Pharma shareholders approved all resolutions at the 11 August 2026 annual general meeting, including the adoption of audited financial statements for the year ended 31 March 2026 and the re-election of two independent non-executive direct...
Jacobson Pharma Sets Out Board Composition and Committee Roles
Aug 11, 2026
Jacobson Pharma Corporation Limited has outlined the composition of its board of directors and detailed the roles and functions of each member across key board committees. The announcement clarifies the responsibilities within the audit, remunerat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.